Speakers
Early confirmed speakers include
Ana Filipa Alexandre, Vice President, Head of Pricing and Market Access, Santen
Amer Al-Taie, Senior Director, Value & Evidence Team Lead, Pfizer
Luigi Angelillo, Director, Market Access EMEA, Argenx
Ad Antonisse, Director, Market Access & External Affairs, AstraZeneca
Diego Ardigò, Global Rare Disease, Research & Development Head & Executive Board Member and Vice Chair, Chiesi Group & EUCOPE
Marnix Artz, Head Patient Access, Pricing & Governmental Affairs, Merck Group
Mr Johnny Bane, Head of Market Access, Accord Healthcare
Alexander Bastian, Vice President, Value & Market Access, A.M. Pharma
Bjørn Bayer, Director, Therapeutic Area CVMRPH, Janssen
Tomer Ben Zaken, Director, Head of Sick Funds & Hospitals Access, Abbvie
Katja Berg, Global Director, Innovative Value and Access Strategy, Global Market Access and Pricing, BBU, AstraZeneca
Nick Besseling, Manager, Value Strategies & Agreements, AstraZeneca
Chris Bidad, Global Head, Access Strategy and Payer Policy, AstraZeneca
Jesper Bjerggren, Associate Director, European Market Access, Teva Pharmaceuticals
Marie-Sharmila Blandino, Director, Global Access Strategy Lead, Amgen
Par Bolina, Adjunct Associate Professor, Medicinal Chemistry, Rutgers University
Thomas Bols, Head of Government Affairs and Patient Advocacy, EMEA, PTC Therapeutics
Anh Bourcet, External Advisor, Market Access Lead, APACMed, Asia Pacific Medical Technology Association
Vidya Breeveld, Independent Market Access Expert
Charles Brown, Director, Global Pricing & Contracting, Novartis
Robert Burley, Director, Care, Campaigns and Support, The Muscular Dystrophy U.K.
Astrid Buys, Director, Global Head of Tenders and Pricing, Bavarian Nordic A/S
Lorenzo Capretto, Market Access Lead, Europe & Emerging Markets, Chiesi
Laurent Carter, Senior Vice President, Head of Global Pricing, Bristol-Myers Squibb
Sandro Cesaro, Head of Europe Market Access & Pricing, AstraZeneca
Mata Charokopou, Senior Director, Global Head of Access, Pricing & Value, Ucb
Alina Charter, VP Market Access, Pricing and Policy, Alnylam
José Luis Sánchez Chorro, Director, Market Access, Spain and Portugal, Jazz Pharmaceuticals
Sally Chung, Vice President, Head of Market Access & Pricing Europe, GSK
Paolo Angelo Cortesi, Assistant Professor in Public Health, Research Centre on Public Health (CESP), University of Milan-Bicocca, Monza, Italy.
Elisa Crovato, Director, Pricing & Market Access, Chiesi Group
Matt Cullen, Vice President, Value, Access & Policy, Apellis Pharmaceuticals
Marcus Dahlman, Head of Market Access Europe, Hansa Biopharma
Nidhi Dani, Director, Global Market Access, Novartis
Michal Davidescu, Health Access Specialist, Pfizer
Michele de Guise, President and Chief Executive Officer, INESSS
Rossella Di Bidino, Head of HTA for AI Unit, Graduate School of Health Economics and Management (ALTEMS)
Toon Digneffe, Head, Public Affairs & Public Policy, Europe & Canada, Takeda
Riad Dirani, Vice President, Global HEOR, Medical Operations & Excellence, Teva Pharmaceuticals
Patricia Dorling, Head, Global HEOR and Real World Evidence, Chiesi Group
Dilesh Doshi, Vice President, Global Health Economics and Outcomes Research, Acadia Pharmaceuticals Inc.
Benjamin Eckert, Senior Vice President, Market Access, Adaptive Biotechnologies
Gina Ewy, VP, Head of Global Market Access, Hansa Biopharma
Marina Faiella, Director, Forecasting and Business Analytics, BeiGene
Diar Fattah, Director, Health Economics and Outcomes Research, Vertex Pharmaceuticals
Sarah Ferry, Senior Policy Advisor, Innovation & Life Sciences, NHS Confederation
Stefaan Fiers, Head of Corporate Communication, Public Affairs & Patient Advocacy, Belgium, Takeda
Kalitsa Filioussi, Global Director, Early Access, Novartis
Lora Fleifel, Director, Market Access Operations, Oncology Europe, Merck
Ishita Gaikwad, Director, Global Integrated Access Strategy, Amgen
Benjamin Gannon, Vice President, International, Guardant Health
Fabrizio Gianfrate, Full Professor, Health Economics and Outcomes Research, Former AIFA
Ramiro Gilardino, Senior Director, Global HTA & Access Policy Lead, MSD
Christoph Glaetzer, Chief Global Value and Access Officer, Janssen
Josie Godfrey, Co-Chief Executive Officer, Realise Advocacy
Thomas Grub, Senior Expert, Global Pricing and Market Access, medac GmbH
Josep Maria Guiu Segura, Director, Pharmacy and Medicines Area, Consortium of health and social care of Catalonia
Marlene Gyldmark, Vice President, Global Head, HEOR & Epidemiology, Idorsia Pharmaceuticals
Matthew Hanchard, Research Associate, University of Sheffield
Gunter Harms, Senior Director, Patient Access, Germany, Austria, Switzerland, Novartis Gene Therapies
Adrian Harrington, Senior Director, Value & Access, Biogen
Thomas Hasmann, Head of Market Access, Europe, KalVista Pharmaceuticals
Birgit Holz, Global Head, Contracting Innovation, Sanofi
Alison Horsfield, Director, Global Access Strategy, AstraZeneca
Kirsty Hoyle, Chief Executive Officer, Metabolic Support UK
Giorgio Iotti, Head Of Program Leadership And Control, Rare Disease Unit, Chiesi Farmaceutici SpA
Dawn Ireland, President & Founder, CDH International
Shrividya Iyer, Independent Expert, RWE and HEOR, Independent Expert
Jayasree Iyer, Chief Executive Officer, Access to Medicine Foundation
Saira Jan, Vice-President & Chief Pharmacy Officer, Blue Cross Blue Shield of New Jersey
Mr Pall Jonsson, Programme Director, Data and Real World Evidence, National Institute for Health & Care Excellence (NICE)
Madhu Kabra, Global Director, Health Economics and Outcomes Research, MKGlobal
Lisette Kaskens, Director, Market Access, Europe, LATAM & Canada, Ferring Pharmaceuticals
Sebastian Kessel, Senior Director, Head of Market Access & External Engagement Germany, UCB
Rob Kettell, Director, Commercial Medicines Negotiation and Complex Transactions, NHS England
Elizabeth Kinter, Vice President, Head of Evidence, Value and Access, Vir Biotechnology
Sandeep Kiri, Global Head, Health Economics and HTA Evidence, Ucb
Jolanda Koenders, Head of New Product Planning, Central Southeast Europe, Takeda
Marianne Laouri, Executive Director, Value Demonstration, Specialty Products & Quality of Care, Boehringer Ingelheim
Agathe Le Lay, Vice President, Head of Global Value Evidence & Patient Insights, Medical Affairs, H. Lundbeck A/S
Timothy Lenehan, Corporate Vice President, Head of Global Market Access, Novo Nordisk
Friedhelm Leverkus, Director, HTA & Outcomes Research, Pfizer
Penny Lovell, Head of Access, Pricing and External Engagement, Ucb
Katja Lundell, Senior Director, Global Head of Pricing, Access and Communications, theramex
Elena Lungu, Manager of Policy Development, Patented Medicine Prices Review Board, Government of Canada
Jörg Mahlich, Market Access and Government Affairs Lead, Miltenyi
Charles Makin, Global Head, Health Economics and Outcomes Research, HTA & Real-World Evidence, Biogen
Shabana Malik, Director, Access, UK & Ireland, BIOMERIEUX
Farzana Malik, Independent Market Access Expert
Chris Mancill, Senior Vice President & Head, Worldwide Value Access, Payment and HEOR, Bristol Myers Squibb
Lorenzo Mantovani, Professor of Public Health, University Of Milano - Bicocca
Marco Marchetti, Co-Chair, HTA Coordination Group & Director, Health Technology Assessment Unit, European Commission & National Agency for Regional Care Services, Italy
Silvy Mardiguian, Senior Director, Head of HEOR, Europe & New Markets, BeiGene
Francesco Marinucci, Director, Global Market Access, Abbott
Jake McDowell, Vice President, Head of Market Access and Pricing, Partner Therapeutics
Sean McElligott, Executive Director, Head, US Health Economics Outcomes Research, Novartis
Erin Mistry, Executive Vice President, Chief Commercial Officer, CorMedix Inc
Lorenzo Montrasio, Senior Scientific Officer, Council of Europe
Paolo Morgese, Head of Public Affairs, Europe, Alliance for Regenerative Medicine
Tal Morginstin, Director, HTA division, Ministry of Health, Israel
Christine Mossa, Senior Director, Regulatory Affairs, Public Affairs, Value & Access, Ipsen Biopharmaceuticals Canada Inc.
Michael Mueller, Head Of Market Access, Western Europe, Sun pharma
Neil Mulcock, Vice President, International Government Affairs and Policy, Gilead Sciences
Bogdan Muresan, Director, Global HEOR, Astellas Pharma
Alexander Natz, Director General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Claudia Neuber, Head of Global Pricing, Oncology, AstraZeneca
Enkeleida Nikai-Fitzgerald, Vice President, Head of Global Real-World Evidence, GenMed, Sanofi
Eric Noehrenberg, Global Vice President, Market Access and Government Affairs, CORCYM
Andrew Olaye, Executive Director, Head of Market Access and Partnership EMEA, Orchard Therapeutics Ltd
Lucinda Orsini, Vice President, Value and Outcomes Research, COMPASS Pathways
Donal O'Sullivan, Vice President, Head of Pricing & Tenders, CSL Vifor
Ipek Ozer-Stillman, Vice President, Global Head, Health Economics, Takeda
Elena Panitti, Global Director, Evidence Valuation and Enablement, Novartis
Michela Pantaleoni, Chief Market Access Officer, Napo Therapeutics
Dilip Patel, VP Market Access, Autolus
Julien Patris, Head of Patient Advocacy and Public Policy, EMEA, arGEN-X
Marco Penske, Head, Market Access & Healthcare Affairs, Germany, Boehringer-Ingelheim
Diogo Teixeira Pereira, Affiliate Member of NOVA SBE, Health Economics & Management Knowledge Center, Universidade NOVA de Lisboa
Tomaso Piaggio, Director, Head of Southern Cluster, International Market Access, Alnylam Pharmaceuticals
Andres Pichon Riviere, Executive Director, Health Technology Assessment And Economic Evaluations, I.E.C.S.
Trine Pilgaard, Director, Head of Market Access, Denmark and Iceland, Pfizer
Carme Pinyol, Early Products and HEOR Lead, Novartis
Lara Pippo, Head Of Market Access & Government Affairs, Italy, CSL Behring
Jonathan Plumb, Vice President, Head, Global Value & Access, Ferring Pharmaceuticals SA
Tanja Podkonjak, Director, Access and Reimbursement Policy, Oncology, EUCAN, Takeda
Mary Lynne Van Poelgeest-Pomfret, President, World Federation For Incontinent Patients
Mr Luca Luigi Polastri, Global Director, Payor Value and Patient Access Head, Kyowa Kirin
Daniella Rahamim-Cohen, Director, Community Medicine, Maccabi Healthcare Services
Marco Rauland, Vice President, Global Head of GVAP Strategic Planning & Data Science, Global Evidence Demonstration, Market Access and Pricing, Merck Group
Laurene Redding, Global Head, Value, Access & Pricing, ex-China, BeiGene
Juan Carlos Rejon-Parrilla, Senior HTA and Health Policy Researcher, Andalusian Regional Department of Health
Rogerio Ribeiro, Senior Vice President, Head of Global Commercial, Vaccines Business Unit, Takeda
Andre Roeder, Head, Global Market Access, TETEC AG
Alexander Roediger, Associate Vice President, Global Lead, Oncology Policy, MSD
Ivanna Rosendal, Senior Director, Head of Commercial and Medical IT, Ascendis Pharma A/S
Shaun Rowark, Associate Director, Data Access and Analysis, NICE
Igor Rudychev, Vice President, Enterprise Analytics, Horizon Therapeutics
Sandrine Ruiz, Senior Director, Market Access, Pricing & HEOR, Immunocore Ltd
Erik Sagdahl, Head of Procurement, Pharmaceutical Division, Sykehusinnkjop
Peter Sajosi, Director, Regional Value and Access Lead, Amgen
Jose Luis Sanchez Chorro, Director, Market Access, Spain and Portugal, Jazz Pharmaceuticals
Steve Sandor, Vice President, Market Access, Government Affairs and Trade, Paratek Pharmaceuticals , Inc.
Eduardo Santos, Executive Director, Therapeutic Area Head, General Medicines, Global Value, Access & Pricing, Amgen
Michael Schlander, Head of Division of Health Economics & Professor of Health Economics, German Cancer Research Center & University of Heidelberg
Fabian Schmidt, Head of Market Access / HEOR, Recordati Rare Diseases Sarl
Ayman Semaan, Market Access & Pricing Lead, Biologix
Shuvayu Sen, Vice President and Head of Oncology, Center of Observational & Real World Evidence, MERCK
Hans Severens, Independent HTA Expert, Former Vice President,, Dutch Health Council
Kun Shi-van Wielink, EMEA Associate Director, HEOR/RWE Market Access, Santen
Simon Shohet, Vice President, Market Access, International, Amicus Therapeutics
Rita Shorjian, Commercial Director, Determatology, Intercontinental, Middle East, Africa and Russia, Abbvie
Matt Slabbert, Vice President, Global Head of Pharma Public Affairs, Bayer
Paul Slobbe, Director, Access and External Affairs, Takeda Nederland B.V.
Jiri Smejkal, Global Head of Pricing and Tender Excellence for PDT, Takeda
Igor Solev, Global Head of Market Access, Policy & External Payer Affairs, Abbott Laboratories
Seema Sondhi, Vice President, Head of Global Strategic Projects, Takeda
Rafael Souza, Director, Access Solutions & Pricing, New Markets, BeiGene
Ulf Staginnus, Vice President, International Market Access & Pricing, Blueprint Medicines
Kim Stephens, Executive Director, Muenzer MPS Research & Treatment Center
Helen Stoop, Senior Director, Head of Patient Advocacy, Europe & Canada, Takeda
Pernille Storm, Vice President, Global Pricing and Market Access, Lundbeck
Rachel Studer, Global Executive Director Launch Evidence, Novartis
Teddy Sun, Evidence Generation Lead, Nordic Data Digital & Technology (DDT), Takeda
Annie Syntosi, Global Associate Director, Value & Access, HEOR, Global Health,, Novartis Pharma AG
Monika Szkultecka-Debek, Vice President, Qualitas Vitae Institute Foundation
Neeta Tandon, Vice President, Value & Evidence Scientific Engagement, Janssen
Tina Taube, Director, Market Access and Orphan Drug Policy Lead, EFPIA
Sheena Thakkar, Director, Value & Evidence, Pfizer
Luca Tofani, Director, Pricing and Reimbursement, S.I.F.I. Spa
Ariella Toren, Director, Medicine and Medical Technologies, HMOS Department, Ministry of Health, Israel
Kaan Tunceli, Vice President and Head, Global Value and Real World Evidence, Otsuka Pharmaceutical
Allister Upton, Director, Market Access and Business Development, EMEA, Alimera Sciences Ltd
Bart Van Den Daele, Director, Market Access, Head of External Affairs, Gilead Sciences
Goedele van Haasteren, Deputy chief Section HTA, Federal Office of Public Health, Switzerland
Chantal van Litsenburg, Manager, Translational Effectiveness, Leiden University Medical Center (Netherlands)
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Medical Advisor, National Evaluation Committee for Specialised Medicine, CZ
Christina Vandorou, Director, Macroeconomics And Health Policy, EMEA, Janssen
Kärt Veliste, Service Manager, Department of Medicines and Medical Devices, Tervisekassa Estonian Health Insurance Fund
Juliette Vila Sinclair/Spence, Rare Disease Patient Advocate & Chairwoman, Acanthamoeba Keratitis Eye Foundation
Keith White, Head, Global Market Access, Amylyx Pharmaceuticals
Kalman Emry Wijaya, Director, Head of Pricing, Tender and Contracting, Biogen
Rhys Williams, Vice President, Evidence Generation Strategy and Health Economics, Global Medical Affairs (ex-China), BeiGene
Durhane Wong-Rieger, President, Chief Executive Officer & Chair, Canadian Organisation for Rare Diseases & Rare Diseases International
Mr Keir Woods, Vice President, Head of Global Market Access and Pricing, Merck Group
Lori Yin, Associate Director, Access Lead, Roche
Zinajda Zolic-Karlsson, Senior advisor HTA, Norwegian Medicines Agency
Get Involved
Sponsorship & Exhibition Sales
David Boore
david.boore@terrapinn.com
+44 20 8164 3052
Conference Production
George Mullens
george.mullens@terrapinn.com
+44 20 8164 3940
Marketing Opportunities
Diana Cobzac
diana.cobzac@terrapinn.com
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events